Preface: The 1st International Electronic Conference on Vaccines—RNA Vaccines, Current Challenges and Future Developments

firstₚage Download PDF settings Order Article Reprints Font Type: Arial Georgia Verdana Font Size: Aa Aa Aa Line Spacing:    Column Width:    Background: Open AccessEditorial Preface: The 1st International Electronic Conference on Vaccines—RNA Vaccines, Current Challenges and Future Developments by François MeurensFrançois Meurens SciProfiles Scilit Preprints. org Google Scholar 1, * and Fanny RenoisFanny Renois SciProfiles Scilit Preprints. org Google Scholar 2 1 Swine and Poultry Infectious Diseases Research Center (CRIPA), Faculty of Veterinary Medicine, University of Montreal, Saint-Hyacinthe, QC J2S 2M2, Canada 2 INRAE, Oniris, BIOEPAR, 44300 Nantes, France * Author to whom correspondence should be addressed. Med. Sci. Forum 2024, 26 (1), 5; https: //doi. org/10. 3390/msf2024026005 Published: 8 April 2024 (This article belongs to the Proceedings of The 1st International Electronic Conference on Vaccines) Download keyboardₐrrowdown Download PDF Download PDF with Cover Download XML Download Epub Versions Notes 1. Introduction 1. 1. Conference IntroductionThe 1st International Electronic Conference on Vaccines: RNA Vaccines, Current Challenges and Future Developments (IECV 2023), was held on 1–15 December 2023. It was an online event, organized by MDPI and Vaccines MDPI at https: //sciforum. net/event/IECV2023. mRNA vaccines have been developed and trialled for cancers and infectious diseases. Although the success of mRNA vaccines has been achieved in the control of COVID-19, there are challenges for their future development. The production of mRNA vaccines requires multiple steps, including mRNA synthesis, purification, and formulation with, e. g. , lipid nanoparticles. Therefore, the stability of intermediate and final products during storage and transportation is a real problem. Breakthrough infections of SARS-CoV-2 variants and the immune evasion of cancers driven by the mutation of antigens expressed from mRNA are the major challenges in development. Since mRNA vaccines have shown advantages compared to others due to the induction of humoral and cellular immune responses and adaptability in viral and tumour antigens, future vaccines should be stabler, safer, and more compatible with other regimens in combination with other options. 1. 2. Scopes and TopicsAll vaccine-related scientists or researchers are welcome to join this event and share their findings around the following general and related themes including the following: Vaccines to counter anti-microbial resistance. Vaccines to eradicate endemic disease-opportunities and challenges. Vaccines to prevent zoonotic transmission-targeting the animal reservoir. Vaccine platforms—advantages and disadvantages. Clinical trial design for reactive and preventive vaccination. Vaccine deployment in outbreak settings—lessons learnedAdvances in vaccine formulation and adjuvantisation. Clinical view on routinisation of RNA vaccines. How do we prepare for vaccines against the as-yet unknown? COVID-19 vaccine hesitancy. Immune response after vaccination against SARS-CoV-2 in patients with chronic diseases. T cell responses in SARS-CoV-2. SARS-CoV-2 variant and vaccines' development. Novel technology and vaccines' development for COVID-19. T cell immunity and HIV-1 pathogenicity. Neurological complications following COVID-19 infection and COVID-19 vaccination. Vaccine hesitancy. Vaccine safety. Vaccine ingredients. Vaccine schedule. Vaccine objections. Vaccines influence on education. Cost-effectiveness of vaccines. Vaccine transportation. Methods of vaccination. Vaccine-related policy. 1. 3. Program and ScheduleMore information can be found at https: //sciforum. net/event/IECV2023? section=#livesessions (accessed on 27 March 2024). 2. Chairs and Committee Members 2. 1. Event Chairs Prof. Dr. François Meurens, Faculty of Veterinary Medicine, University of Montreal, Canada. Dr. Fanny Renois, INRAE, Oniris, BIOEPAR, France. 2. 2. Session ChairsDr. Silvio Tafuri, Aldo Moro University of Bari, Italy. Prof. Dr. Martin J. D'Souza, Mercer University, USA. Dr. Siddappa N. Byrareddy, University of Nebraska Medical Center, USA. Dr. Daniel Dory, ANSES, France. Dr. Angelos Hatzakis, National and Kapodistrian University of Athens Medical School, Greece. 2. 3. Event CommitteesDr. Dimitris Zavras, University of West Attica, Greece. Dr. Miaomiao Shi, University of Chicago, USA. Dr. Gagandeep Saggu; Institute of Allergy and Infectious Disease, USA. Dr. Gregory Simons, Turiba University, Latvia. Dr. Evangelia Stalika, Aristotle University of Thessaloniki/International Hellenic University, Greece. Dr. Mark Znin, The University of Hong Kong. Hongkong. Dr. Jon Salmanton-García, University of Cologne, Germany. Dr. Yin Li, Yangzhou University, China. Dr. Carrie Long, National Institute of Allergy and Infectious Diseases, USA. 3. Speakers 3. 1. Keynote SpeakerProf. Dr. Ger Rijkers, University College Roosevelt/St. Elisabeth Hospital, The Netherlands. 3. 2. Invited SpeakersProf. Dr. Hidehiro Fukuyama, Kansai Medical School, Japan. Prof. Dr. S. Louise Cosby, Queen's University Belfast, UK. Prof. Dr. Ranjit Ray, Saint Louis University, USA. Prof. Dr. Silvio Tafuri, Aldo Moro University of Bari, Italy. Prof. Dr. Vishwanath Venketaraman, Western University of Health Sciences, USA. 4. Statement of Peer ReviewIn submitting conference proceedings to Medical Sciences Forum, the volume editors of the proceedings certify to the publisher that all papers published in this volume were subjected to peer review administered by the volume editors. Reviews were conducted by expert referees to the professional and scientific standards expected of a proceedings journal. Type of peer review: single blind. Conference submission management system: sciforum. Number of submissions sent for review: 64. Number of submissions accepted: 6. Number of published: 4. Acceptance rate (number of submissions accepted/number of submissions received): 9. 3%. Average number of reviews per paper: 1. Total number of reviewers involved: 10. Peer review criteria and process: peer review policy and guidelines can be found at https: //www. mdpi. com/journal/msf/instructionforconferenceₒrganizers. Conflicts of InterestThe authors declare no conflicts of interest. Disclaimer/Publisher's Note: The statements, opinions and data contained in all publications are solely those of the individual author (s) and contributor (s) and not of MDPI and/or the editor (s). MDPI and/or the editor (s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. © 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https: //creativecommons. org/licenses/by/4. 0/). Share and Cite MDPI and ACS Style Meurens, F. ; Renois, F. Preface: The 1st International Electronic Conference on Vaccines—RNA Vaccines, Current Challenges and Future Developments. Med. Sci. Forum 2024, 26, 5. https: //doi. org/10. 3390/msf2024026005 AMA Style Meurens F, Renois F. Preface: The 1st International Electronic Conference on Vaccines—RNA Vaccines, Current Challenges and Future Developments. Medical Sciences Forum. 2024; 26 (1): 5. https: //doi. org/10. 3390/msf2024026005 Chicago/Turabian Style Meurens, François, and Fanny Renois. 2024. "Preface: The 1st International Electronic Conference on Vaccines—RNA Vaccines, Current Challenges and Future Developments" Medical Sciences Forum 26, no. 1: 5. https: //doi. org/10. 3390/msf2024026005 Article Metrics No No Article Access Statistics Multiple requests from the same IP address are counted as one view.